Shares of Profound Medicl (NYSE:PROF) have received a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

Analysts have set a one year consensus price objective of $21.67 for the company and are anticipating that the company will post ($0.22) EPS for the current quarter, according to Zacks. Zacks has also assigned Profound Medicl an industry rank of 85 out of 254 based on the ratings given to related companies.

Several analysts have issued reports on PROF shares. Cowen assumed coverage on Profound Medicl in a research note on Wednesday, April 1st. They issued an “outperform” rating and a $15.00 target price on the stock. Mackie downgraded shares of Profound Medicl from a “buy” rating to a “hold” rating in a report on Tuesday, April 7th. Raymond James boosted their price target on shares of Profound Medicl from $35.00 to $38.00 and gave the company a “strong-buy” rating in a research report on Friday. Finally, Zacks Investment Research cut shares of Profound Medicl from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th.

PROF traded up $1.72 during midday trading on Friday, reaching $16.08. The company had a trading volume of 107,460 shares, compared to its average volume of 69,768. Profound Medicl has a 12-month low of $5.00 and a 12-month high of $20.60. The business has a 50-day moving average price of $12.70 and a two-hundred day moving average price of $12.38.

Profound Medicl (NYSE:PROF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.62 million.

Several institutional investors have recently made changes to their positions in the company. Redmile Group LLC acquired a new stake in Profound Medicl in the first quarter valued at $3,896,000. Morgan Stanley boosted its position in shares of Profound Medicl by 331.0% during the 1st quarter. Morgan Stanley now owns 13,188 shares of the company’s stock worth $129,000 after acquiring an additional 10,128 shares in the last quarter. CIBC World Markets Inc. purchased a new position in shares of Profound Medicl in the 1st quarter valued at about $127,000. Two Sigma Investments LP acquired a new stake in shares of Profound Medicl during the 1st quarter worth about $141,000. Finally, Blackcrane Capital LLC purchased a new stake in Profound Medicl during the first quarter worth approximately $2,167,000.

About Profound Medicl

Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.

Read More: What does cost of debt say about a company’s financial health?

Get a free copy of the Zacks research report on Profound Medicl (PROF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with's FREE daily email newsletter.